GlassScriptPhysician profile
Elizabeth B Chambers
NPI 1598848475
$3,016.85
in general payments reported to CMS, 2019-2025
18 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $393 · 2021: $616 · 2022: $482 · 2023: $314 · 2024: $508 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,063.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,062.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $751.94 | 2019-2024 | Austedo Xr, Uzedy |
| Otsuka America Pharmaceutical, INC. | $297.53 | 2019-2024 | Rexulti |
| Allergan, INC. | $282.55 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $261.77 | 2023-2025 | Nuplazid, Daybue |
| Janssen Pharmaceuticals, INC | $256.54 | 2019-2023 | Spravato |
| Abbvie INC. | $255.51 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $251.57 | 2021-2023 | Caplyta |
| Supernus Pharmaceuticals, INC. | $197.07 | 2021-2024 | Qelbree, Qelbree |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2025 | Cobenfy |
| Alkermes, INC. | $90.13 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $60.53 | 2019-2023 | Jornay Pm |
| Vanda Pharmaceuticals INC. | $44.78 | 2020-2021 | |
| Eisai INC. | $35.86 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.95 | 2022-2023 | Trintellix |
| Biogen, INC. | $22.65 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $20.91 | 2023 | Adlarity |
| Lundbeck LLC | $15.84 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.72 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Chambers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.